| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- FEMS Immunol. Med. Microbiol. (1)
- J. Antimicrob. Chemother. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Abe S et al. | Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. | 2000 | Am. J. Respir. Cell Mol. Biol. | pmid:10615065 |
| Kiyota K et al. | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. | 1999 | J. Gastroenterol. | pmid:10616771 |
| Aoyama N et al. | Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. | 1999 | J. Gastroenterol. | pmid:10616772 |
| Gotoda T et al. | Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. | 1999 | J. Gastroenterol. | pmid:10616774 |
| Maeda S et al. | Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. | 2000 | J. Clin. Microbiol. | pmid:10618089 |
| Rocha RT et al. | Comparison of spiramycin and clarithromycin for community-acquired lower respiratory tract infections. | 1999 | Int. J. Clin. Pract. | pmid:10622070 |
| Lugannani C and Strickland C | Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? | 1999 | J Fam Pract | pmid:10628582 |
| Bui KQ et al. | In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. | 2000 | J. Antimicrob. Chemother. | pmid:10629013 |
| Blondon H | [Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?]. | 1999 | Presse Med | pmid:10629694 |
| Cammarota G et al. | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. | 1999 | Dig. Dis. Sci. | pmid:10630486 |
| Bortolotti M et al. | Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1999 | Dig. Dis. Sci. | pmid:10630494 |
| Burgess DS et al. | A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. | 1999 | Ann Pharmacother | pmid:10630825 |
| Juurlink DN and Ito S | Comment: clarithromycin-digoxin interaction. | 1999 | Ann Pharmacother | pmid:10630847 |
| Hoshiya S et al. | Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. | 2000 | J. Gastroenterol. | pmid:10632534 |
| Fujioka T | Clarithromycin resistance in Helicobacter pylori: implications for therapy. | 2000 | J. Gastroenterol. | pmid:10632546 |
| Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
| Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
| Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Keiser P et al. | A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. | 1999 | Int J STD AIDS | pmid:10639059 |
| Miyanohara T et al. | Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. | 2000 | Laryngoscope | pmid:10646728 |
| Graham DY et al. | Furazolidone combination therapies for Helicobacter pylori infection in the United States. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651662 |
| Wong BC et al. | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651663 |
| Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
| Chiba N and Marshall CP | Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. | 2000 | Can. J. Gastroenterol. | pmid:10655024 |
| Alarcón T et al. | PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. | 2000 | J. Clin. Microbiol. | pmid:10655418 |
| Allevi P et al. | A new convenient transformation of erythromycin A into clarithromycin. | 1999 | Bioorg. Med. Chem. | pmid:10658579 |
| Yatsunami J et al. | Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. | 1999 | Cancer Lett. | pmid:10660084 |
| Hoshi T et al. | Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis. | 1999 | Hum. Pathol. | pmid:10667417 |
| Mordi MN et al. | Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy. | 2000 | J. Med. Chem. | pmid:10669574 |
| Griffith DE et al. | Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. | 2000 | Clin. Infect. Dis. | pmid:10671330 |
| Miyabayashi H et al. | Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori. | 2000 | Helicobacter | pmid:10672049 |
| Dammann HG et al. | Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. | 2000 | Helicobacter | pmid:10672051 |
| Calvet X et al. | Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study. | 2000 | Helicobacter | pmid:10672052 |
| Sevin E et al. | [Helicobacter pylori: identification and detection of clarithromycin resistance by gene amplification]. | 2000 Jan-Feb | Ann. Biol. Clin. (Paris) | pmid:10673617 |
| Kohri K et al. | Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. | 2000 | Eur. Respir. J. | pmid:10678622 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Suleymanlar I et al. | Response to triple treatment with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients. | 1999 | Adv Perit Dial | pmid:10682076 |
| Sugimoto M et al. | Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. | 2000 | Am. J. Gastroenterol. | pmid:10685780 |
| Gotfried MH | Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. | 2000 | Clin Ther | pmid:10688386 |
| Bayerdörffer E | [The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol]. | 2000 | Z Gastroenterol | pmid:10689750 |
| Szlachcic A et al. | Helicobacter pylori and its eradication in rosacea. | 1999 | J. Physiol. Pharmacol. | pmid:10695558 |
| Georgopoulos SD et al. | Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. | 2000 | Dig. Dis. Sci. | pmid:10695615 |
| Dore MP et al. | Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. | 2000 | Dig. Dis. Sci. | pmid:10695616 |
| Miwa H et al. | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. | 2000 | Dig. Dis. Sci. | pmid:10695617 |
| Shamaly H et al. | Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis. | 2000 | J. Pediatr. Gastroenterol. Nutr. | pmid:10697140 |
| Ives TJ et al. | In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers. | 2000 | J. Antimicrob. Chemother. | pmid:10702548 |
| Schweeger I et al. | Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers. | 2000 | Thromb. Res. | pmid:10704650 |